kringle-pharmaCo., Ltd.

NEWS

notice

Jul 20, 2020 Notice

Kringle initiates Phase 3 clinical trial of recombinant human HGF for the treatment of acute spinal cord injury.

Kringle initiates Phase 3 clinical trial of recombinant human HGF for the treatment of acute spinal cord injury.